· In January, Dapoxetine hydrochloride tablets have been approved for market launch;
· In February, Gabapentin capsules have been approved for market launch;
· In April, Okazepine tablets have been approved for market launch;
· In June,Lacosamide tablets have been approved for market launch;
· In October, Haloperidol injection has been approved for market launch;
· In December,Haloperidol tablets have been approved for market launch;
· Application for Listing: 7 Varieties;
· In July,Lamotrigine tablets and Alogliptin Benzoate tablets have been approved for market launch;
· In October, Ebastine tablets and Fluvoxamine Maleate tablets have been approved for market launch;
· In December,Atenolol tablets have been approved for market launch;
· In December,Factory expansion construction begins;
· Application for Listing: 12 Varieties, 15 Product Specifications;
· In July，Apixaban tablets were approved for market;
· Application for listing: 9 products, 14 specifications;
· Obtained project approval for the second-class psychotropic drug Oxycodone and Acetaminophen Sustained-release Tablets；
· Our company has received the first review for Phenobarbital tablets;
· Application for listing: 1 product, 2 specifications;
· Implemented registration verification and production of 16 new counterfeit products;
· Application for listing: 1 variety, 1 specification;
· Obtained project approval for the second-class psychotropic drug Chlorpheniramine Tablets;
· Shanghai JinShan Phammaceutical Ltd was renamed "CCP".
· The factory has passed GMP certification.
· Shanghai Municipal Drug Administration approved the transfer of the company's product approval documents.
· Shanghai Jinshan Pharmaceutical obtained the "Drug Production License".
· Merge Shanghai Aike Pharmaceutical and move the company to No. 428, Xihan Road, Fengxian District;The company has obtained the corresponding production qualification.
· The company obtained the Pharmaceutical GMP Certificate.
· Shanghai JinShan Phammaceutical Ltd was established